Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction

Bibliography

• DEWOOD MA, SPORES J, NOTSKE R et al.: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl. J Med. (1980) 303:897–902.
   PubMed Web of Science ®Google Scholar
• COLLEN D: Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation (1996) 93:857–865.
   PubMed Web of Science ®Google Scholar
• COLLEN D, HABER E: The fibrinolytic system andthrombolytic therapy. In: Molecular Basis of Cardiovas-cular Disease. A companion to Braunwald's Heart Disease. Chien EW (Ed.), WB Saunders Publications (1999):537–565.
   Google Scholar
• BRAUNWALD E: The open-artery theory is alive and N Engl. J Med. (1993) 329:1650–1652.
   Google Scholar
• CANNON CP: Optimizing the medical management of acute coronary syndromes. J. Thromb. Thrombolysis (1999) 7:171–189.
   PubMed Web of Science ®Google Scholar
• GRUPPO ITALIANO PER LO STUDIO DELLA STREPTOCHI-NASI NELL'INFARTO MIOCARDICO (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet (1986) 1:397–401.
   PubMed Web of Science ®Google Scholar
• GLOBAL UTILIZATION OF STREPTOKINASE, AND TISSUEPLASMINOGEN ACTIVATOR FOR OCCLUDED CORONARY ARTERIES (GUSTO) INVESTIGATORS: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarc-tion. N Engl. J. Med (1993) 329:673–682.
   PubMed Web of Science ®Google Scholar
• THE GUSTO ANGIOGRAPHIC INVESTIGATORS: Theeffects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarc-tion. N Engl. J. Med. (1993) 329:1615–1622.
   PubMed Web of Science ®Google Scholar
• SIMES RJ, TOPOL EJ, HOLMES DR et al: link between theangiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation (1995) 91:1923–1928.
   PubMed Web of Science ®Google Scholar
• LARSEN GR, TIMONY GA, HORGAN PG et al.: Proteinengineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol. Chem. (1991) 266:8156–8161.
   PubMed Web of Science ®Google Scholar
• COLLEN D, STASSEN J-M, LARSEN G: Pharmacokineticsand thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood (1988) 71:216–219.
   PubMed Web of Science ®Google Scholar
• LARSEN GR, METZGER M, HENSON K, BLUE Y, HORGANP: Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood (1989) 73:1842–1850.
   PubMed Web of Science ®Google Scholar
• HANSEN L, BLUE Y, BARONE K, COLLEN D, AND LARSENGR: Functional effects of asparagine-linked oligosac-charide on natural and variant human tissue-type plasminogen activator. J Biol. Chem. (1988) 263 :15713–15719.
   PubMed Web of Science ®Google Scholar
• Investigator Brochure Lanoteplase (BMS-200980). Version No. 4 (April 6 1998) Data on file, Bristol-Myers Squibb.
   Google Scholar
• Phase-II safety and efficacy of SUN9216 by iv. bolus injection in patients with acute myocardial infarction: a multi-center study of clinical Phase-II. Suntory Limited Protocol No BA 2201 Draft Report.
   Google Scholar
• YUI Y, SAOKY N, IWADE K et al.: A double-blind, dose-finding study for the iv. bolus injection of SUN9216 (modified tissue plasminogen activator) in acute myocardial infarction: clinical late Phase-II study. Jpn. Pharmacol. Ther. (1997) 25:245–271.
   Google Scholar
• YUI Y, KAWAI T, HOSODA S et al.: Clinical efficacy of SUN9216 (modified tissue plasminogen activator) as compared to alteplase in patients with acute myocar-dial infarction: a multicenter randomized double-blind comparative study. Jpn. Pharmacol. Ther. (1997) 25:269–302.
   Google Scholar
• DEN HEUER P, VERMEER F, AMBROSIONI E et al. (FORTHE INTIME INVESTIGATORS): Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction. Circulation (1998) 98:2117–2125.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM, WILCOX RG, GIUGLIANO RP et al.: Long-term Comparison of Lanoteplase and Alteplase in ST Elevation Myocardial Infarction: 6 Month Follow-up in the InTIME-II Trial. Circulation (1999) 100:1–498.
   Google Scholar
• GIUGLIANO RP, ANTMAN EM, MCCABE CH et al.: Omission of heparin bolus lowers rate of intracranial hemorrhage with lanoteplase. J. Am. Coll. Cardiol. (2000) 35 (Suppl. A):407A.
   Google Scholar
• PAONI NF, STEINMETZ HG, GILLETT N et al.: An experi-mental model of intracranial hemorrhage during thrombolytic therapy with t-PA. Thromb. Haemost. (1996) 75:820–826.
   PubMed Web of Science ®Google Scholar
• GRANGER CB, HIRSCH J, CALIFF RM et al.: Activatedpartial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation (1996) 93:870–878.
   PubMed Web of Science ®Google Scholar
• GIUGLIANO RP, MCCABE CH, ANTMAN EM et al.: LowerDose Heparin with Fibrinolysis is Associated with Lower Rates of Intracranial Hemorrhage. Am. Heart J. (2000). (In Press).
   Google Scholar
• GISSI-2: a factorial randomised trial of alteplase versusstreptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet (1990) 336:65–71.
   Google Scholar
• ASSESSMENT OF THE SAFETY AND EFFICACY OF A NEWTHROMBOLYTIC (ASSENT-2) INVESTIGATORS: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet (1999) 354:716–722.
   PubMed Web of Science ®Google Scholar